Obesity pill Orforglipron data expected in April 2025: Eli Lilly exec

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-06-11 12:49 GMT | Update On 2024-06-11 12:49 GMT

London: Eli Lilly executive said that data from the late-stage trial of their experimental obesity pill, orforglipron, is anticipated to be released in April 2025.

The pill is part of a class of drugs known as incretins designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow the rate at which the stomach empties of food and decrease appetite.

Drugs from the class are also being tested to treat Alzheimer's.

According to a Reuters report, Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman Sachs healthcare conference, said his company is not convinced that the drug will help with the disease itself, but might help with underlying conditions like obesity and stroke that lead to cognitive decline.

Read also: No major concerns raised by USFDA staff on Eli Lilly Alzheimer's drug Donanemab

Meidcal Dialogues team had earlier reported that Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, had collaborated with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Obesity pill Orforglipron data expected in April 2025: Eli Lilly exec

Similar News